Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors

Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors

Shots:

  • Tilt initiates the collaboration with Merck KGaA & Pfizer to evaluate TILT-123 with avelumab in patients with solid tumors refractory to routine modalities
  • TILT-123 will evaluate for solid tumors in the US & Europe and preclinical results of the dual combination, TILT technology and anti-PDL1 agent demonstrated immune activation & efficacy
  • Bavencio (avelumab) is an anti-PD-L1 antibody act by blocking the interaction of PD-L1 with PD-1 receptors, co-develop & co-commercialize by Merck KGaA & Pfizer under the agreement signed in Nov’14. TILT-123 is an oncolytic adenovirus, replicates only in cancer cells producing immunostimulatory cytokines locally at the tumor site

Click here to read full press release/ article | Ref: Business Wire | Image: Owler